Clinical Trial Detail

NCT ID NCT03360890
Title Synergy of Pembrolizumab Anti-PD-1 Immunotherapy With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Chicago

salivary gland cancer

thyroid gland cancer


Docetaxel + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.